Alembic Pharmaceuticals Limited
APLLTD · Capital Goods · NSE
₹737
Current Market Price
Fair Value (DCF)
₹580
Discount to FV
-21.3%
Updated just now
YieldIQ Score
41/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
44%
ROE
11.9%
Debt/Equity
0.25
WACC
9.8%
Market Cap
₹14,491 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.6%
Return on capital employed
EV / EBITDA
12.9×
Enterprise multiple
Debt / EBITDA
1.1×
Leverage vs earnings
Interest Coverage
10.0×
EBIT covers interest
Current Ratio
1.69×
Short-term liquidity
Asset Turnover
0.91×
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.2%
3-year revenue growth
Revenue CAGR (5Y)
5.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹737.2
Bear case
Discount -114.1%
Base case
Discount -27.1%
Bull case
Discount +6.3%
Ratio Trends
APLLTD · last 9 annual periods
ROE
11.9%
ROCE
15.6%
Operating Margin
—
Debt / Equity
0.25×
PE
19.3×
EV / EBITDA
12.9×
Historical Financials
APLLTD · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹5232 Cr | ₹5500 Cr | ₹6112 Cr | ₹6672 Cr | ₹7345 Cr | +8.9% |
| EBITDA | ₹930 Cr | ₹680 Cr | ₹961 Cr | ₹1065 Cr | ₹1106 Cr | +4.4% |
| EBIT | ₹638 Cr | ₹436 Cr | ₹689 Cr | — | — | +1.9% |
| PAT | ₹521 Cr | ₹342 Cr | ₹616 Cr | ₹583 Cr | ₹675 Cr | +6.7% |
| EPS (diluted) | ₹27.76 | ₹17.40 | ₹31.33 | — | — | +3.1% |
| CFO | ₹552 Cr | ₹724 Cr | ₹803 Cr | ₹88.0 Cr | ₹783 Cr | +9.1% |
| CapEx | ₹-426 Cr | ₹-443 Cr | ₹-327 Cr | ₹-564 Cr | ₹-495 Cr | — |
| FCF | ₹127 Cr | ₹281 Cr | ₹476 Cr | ₹-476 Cr | ₹288 Cr | +22.8% |
| Total Assets | ₹7122 Cr | ₹6183 Cr | ₹6446 Cr | ₹7773 Cr | ₹8763 Cr | +5.3% |
| Total Debt | ₹717 Cr | ₹722 Cr | ₹513 Cr | ₹1258 Cr | ₹1430 Cr | +18.8% |
| Shareholders' Equity | ₹5238 Cr | ₹4370 Cr | ₹4818 Cr | ₹5191 Cr | ₹5675 Cr | +2.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
APLLTD vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 CAPLIPOINT CAPLIPOINT | — | — | Pending | 17.9% | 17.8× |
 JUBLPHARMA JUBLPHARMA | — | — | Pending | 5.6% | 32.5× |
ALIVUS ALIVUS | — | — | Pending | 16.9% | — |
 COHANCE COHANCE | — | — | Pending | 4.6% | — |
 NATCOPHARM Natco Pharma Limited | +175.0% | 40 | Below Fair Value | 15.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹54.00/sh
Last payout
2025-07-29
₹11.00
Peak payout
₹14.00
Trailing yield
1.49%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Alembic Pharmaceuticals Limited (APLLTD.NS) trades at 737.20 vs a model fair value of 580.17, a gap of -21.3%. Piotroski F-score: 4/9. Mo...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of APLLTD →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for APLLTD →
Compare
Head-to-head with peers
Compare APLLTD side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse APLLTDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.